cefuroxime dr. eberth 1500 mg powder for solution for injection/infusion
dr. friedrich eberth arzneimittel gmbh am bahnhof 2, ursensollen 92289, germany - cefuroxime sodium - powder for solution for infusion or injection - cefuroxime sodium 1500 mg - antibacterials for systemic use
omegapharm acetylcysteine solution
omegapharm - acetylcysteine -
mitomycin omegapharm mitomycin powder for injection 20mg vial
omegapharm - mitomycin, quantity: 20 mg - injection, powder for - excipient ingredients: mannitol - mitomycin is indicated in the palliative treatment of carcinoma of the stomach, pancreas, colon, lung (non-small cell), breast, cervix, head and neck, liver and bladder.
mitomycin omegapharm mitomycin powder for injection 10mg vial
omegapharm - mitomycin, quantity: 10 mg - injection, powder for - excipient ingredients: mannitol - mitomycin is indicated in the palliative treatment of carcinoma of the stomach, pancreas, colon, lung (non-small cell), breast, cervix, head and neck, liver and bladder.
mitomycin omegapharm mitomycin powder for injection 2mg vial
omegapharm - mitomycin, quantity: 2 mg - injection, powder for - excipient ingredients: mannitol - mitomycin is indicated in the palliative treatment of carcinoma of the stomach, pancreas, colon, lung (non-small cell), breast, cervix, head and neck, liver and bladder.
omegapharm acetylcysteine solution 200 mg/ml
omegapharm - acetylcysteine -
virbagen omega
virbac s.a. - recombinant omega interferon of feline origin - immunostimulants, - dogs; cats - dogsreduction of mortality and clinical signs of parvovirosis (enteric form) in dogs from one month of age.catstreatment of cats infected with feline leukaemia virus (felv) and / or feline immunodeficiency virus (fiv), in non-terminal clinical stages, from the age of nine weeks. in a field study conducted, it was observed that there was:a reduction of clinical signs during the symptomatic phase (four months);a reduction of mortality:in anaemic cats, mortality rate of about 60% at four, six, nine and 12 months was reduced by approximately 30% following treatment with interferon;in non-anaemic cats, mortality rate of 50% in cats infected by felv was reduced by 20% following treatment with interferon. in cats infected by fiv, mortality was low (5%) and was not influenced by the treatment.
virbagen omega 10
virbac new zealand limited - recombinant feline omega interferon - recombinant feline omega interferon 10,000 thou iu/ml - immune stimulant
sure result o3d3 system- omega-3-acid ethyl esters kit
international brand management, llc - omega-3-acid ethyl esters (unii: d87ygh4z0q) (omega-3 fatty acids - unii:71m78end5s) - omega-3-acid ethyl esters 1 g in 1 g - each capsule contains 1 gram of omega-3-acid ethyl esters liquid concentrate consisting of at least 900 mg of omega-3-acid ethyl esters.
lovaza- omega-3-acid ethyl esters capsule, liquid filled
atlantic biologicals corps - omega-3-acid ethyl esters (unii: d87ygh4z0q) (omega-3 fatty acids - unii:71m78end5s) - omega-3-acid ethyl esters 900 mg - lovaza® (omega-3-acid ethyl esters) is indicated as an adjunct to diet to reduce triglyceride (tg) levels in adult patients with severe (greater than or equal to 500 mg per dl) hypertriglyceridemia (htg). usage considerations: patients should be placed on an appropriate lipid-lowering diet before receiving lovaza and should continue this diet during treatment with lovaza. laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with lovaza. every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy. limitations of use: the effect of lovaza on the risk for